Myriad-PGRN Research Grant

Grant Deadlines

Submission Deadline: January 3, 2023

Grant Award Announcement: February 2023

Project Period: 12 months from funding date

Grant Award: Up to $20,000

Project initiation: April 2023


The mission of the Myriad-PGRN Research Grant is to 
fund research in pharmacogenomics for mental health. One grant up to $20,000 will be awarded on a competitive basis to PGRN members.

Possible topics include (but are not restricted to):

  • Evaluation of under-examined variants in pharmacokinetic genes on psychotropic medication blood levels/response in diverse and under-studied populations
  • In vitro pharmacology studies of the impact of genetic variation on response to psychotropic medications
  • Collaborative arrangements between PGRN members to study PGx in mental health
  • PGx phenoconversion due to drug-drug interaction
  • Evaluation of variants in pharmacodynamic genes on psychotropic medication response or side effects.
  • Studies of implementation of PGx in a mental health setting
  • Research syntheses such as meta-analyses which evaluate studies of mental health PGx.
  • Proposals that include participants from diverse, under-represented minorities, and/or underinsured populations will be prioritized (*see definitions below).

Financial and Reporting Information

It is anticipated that one Myriad-PGRN Research Grant will be awarded this year. The funding can be used for a variety of purposes but is expected to be used for effort for individuals to collect, clean, merge, analyze, or publish data. Funding for additional genotyping in pharmacogenetic validation studies or for investigator/librarian time to develop a high-quality meta-analysis on a broad mental health PGx topic, for example, are acceptable. The awardees will be required to present the results of their research at a future PGRN Research in Progress Symposium and/or PGRN Annual Meeting.

Myriad will have no requirements for data or publication approval as part of this program as it is not intended to utilize Myriad products or data. Myriad hopes to facilitate high quality research in this field through this PGRN grant program.

*Definitions of diversity and underserved for this RFA:

  • "Diversity" refers to the inclusion of patients who come from racial or ethnic minority populations, underserved populations, or populations who experience poorer medical outcomes.
  • “Minority” refers to the inclusion of patients who come from the following minority racial/ethnic populations: African American or Black, Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander (e.g., Guam, Tonga), or Latino or Hispanic. (Link).
  • "Underserved" refers to populations who are "medically underserved” as defined by the Health Resources and Services Administration (HRSA) (Link).


PI(s) must be PGRN members. An individual can be listed as a PI or MPI on only one proposal to the Myriad-PGRN Research Grant. Trainees are eligible with faculty sponsorship documented in a letter of support.

No more than 4 pages, excluding references, budget justification, and letters of support, assembled in a single .pdf

The following sections should be included in your proposal. Applicants have flexibility in the organization but all sections are required.

1. Aims (no more than 1 page)

2. Background and Significance

3. Mental Health Impact of the proposal

4. Research strategy and approach (including statistical analysis). Studies focused on diverse and understudied populations are encouraged.

5. Long term plan to pursue future funding

6. Timeline – project completion is expected 12 months after the initial award. A 6 month no cost extension may be requested with appropriate justification.

Budget and justification
Half page, not included in 4 page limit

Provide a detailed budget and justification that will be considered in the review. Budgets should be realistic and any additional funds available to contribute to the project should be discussed. Equipment is allowed if well justified. Indirect costs are not allowed. If institutions mandate indirect funding, please reach out to the grants administrator for further discussion (

Criteria for Review

Proposals will be reviewed on the basis of scientific merit and significance, study design and analysis, impact on mental health PGx, qualifications of the investigator team, and the potential for future funding. Proposals that include participants from diverse, understudied, and underinsured populations will be prioritized. Trainees are encouraged to apply and will be considered early-stage investigator status during review.

Proposals will be reviewed by a Grant Review Committee composed of PGRN members with appropriate expertise in mental health practice and/or research. Each proposal will be reviewed by at least two reviewers and scores will be reviewed for prioritization for funding by the entire review panel. Reviewer comments will be shared with all applicants after the final funding decision. The final selection for funding will be made by the PGRN Executive Council.


Combine the materials mentioned above into a single .pdf

Send as an attachment to:

Deadline: Midnight (EST) on January 3, 2023

Copyright © 2020 the Pharmacogenomics Global Research Network. All Rights Reserved.

PGRN is a 501(c)3 Non-Profit Association

Follow PGRN
on Social Media

Become a Member

PGRN logo
Membership dues are vital to continue the mission and work of the PGRN. Join your colleagues today and suport the work of PGRN. 
Powered by Wild Apricot Membership Software